RevenanasBook a free audit

Signal

Eli Lilly Q3 2026: Revenue Up 39% YoY, FY Guidance Raised to $91-92B

October 29, 2026

Biotech

Signal

Key Facts

Signal Type

Signal

Industry

Biotech

Companies

Eli Lilly (LLY)

Date

October 29, 2026

Key Earnings Metrics

Eli Lilly (LLY) earnings snapshot
MetricReportedContext
Q3 Revenue Growth39%Year-over-year revenue increase driven by Mounjaro and Zepbound
Mounjaro+Zepbound Revenue>$16BCombined Q3 revenue, $6B growth vs Q3 2025
Gross Margin84.4%Up 80 bps YoY on favorable product mix
FY2026 Revenue Guidance$91-92BRaised full-year guidance on strong portfolio performance

Eli Lilly (LLY) Q3 2026 year-over-year earnings growth chart

Eli Lilly delivered its strongest quarter of 2026, with revenue growing 39% year-over-year and the combined Mounjaro and Zepbound franchise crossing $16B in a single quarter. Gross margin expansion and operating leverage pushed non-GAAP performance margin above 54%, supporting another upward revision to full-year guidance.

  • Revenue grew 39% YoY, adding nearly $7B versus Q3 2025, with key product revenue up over $6B. Volume growth from incretins drove the majority of the increase.
  • Mounjaro and Zepbound combined revenue exceeded $16B, a $6B increase year-over-year. This franchise alone now contributes more than many mid-cap biotech companies generate annually.
  • Gross margin reached 84.4%, up 80 basis points, reflecting favorable product mix toward higher-margin incretins and improved manufacturing costs.
  • Non-GAAP performance margin was 54.2%, up 5.9 percentage points from Q3 2025. Revenue scale is converting to operating leverage faster than prior guidance implied.
  • Non-GAAP EPS was $7.48, including $4.57 in acquired R&D charges from the AtaiBeckley and Merida acquisitions, compared to $7.02 in Q3 2025.
  • Full-year 2026 revenue guidance raised to $91-92B, with non-GAAP EPS guidance of $35-36 and performance margin of 52-52.5%.

U.S. revenue grew 34%, primarily on Zepbound and Mounjaro volume, partially offset by a 7% price decline. Excluding a favorable rebate adjustment, U.S. price declined 10%, confirming that realized pricing remains a structural headwind even as volume accelerates.

International growth was even faster. Europe revenue grew 29% in constant currency, Japan 26%, China 62%, and rest of world 87%. Mounjaro became the first medicine in China to exceed $1B revenue in its first full year, a notable milestone for market penetration in a historically difficult region.

Management Commentary

CEO Dave Ricks described Q3 as another quarter of solid execution, pointing to raised guidance, pipeline advancement, and manufacturing expansion as the three pillars of the period. He emphasized that oncology, immunology, and neuroscience portfolio revenue doubled versus last year, reducing dependence on incretins alone.

The Medicare GLP-1 Bridge Program, launched July 1, has already seen more than half a million prescriptions filled. Among new bridge patients, seven out of ten are starting on a Lilly obesity medicine, giving the company an early share lead in this expanded access channel.

Ricks cited a USC Schaeffer Center estimate that Medicare anti-obesity medication expansion could deliver over $20B in cumulative savings over ten years. This data point matters because it gives policymakers a fiscal argument for broader coverage, which would directly benefit Lilly's obesity franchise.

CFO Lucas Montarce noted that 2026 benefited from approximately $2B in one-time items, including milestone payments and rebate estimate changes, that will not recur in 2027. He flagged net realized price as an expected 2027 headwind, partially offset by volume growth from the Bridge Program and Foundayo launches.

On the pipeline front, Chief Scientific Officer Dan Skovronsky highlighted retatrutide's TRANSCEND-T2D-2 results, where the triple agonist delivered 20-21% weight loss versus 9.4% for semaglutide. He also presented EloraTZP phase II data showing 23.3% weight loss at 48 weeks, 57% more than tirzepatide alone.

Skovronsky acknowledged that the highest EloraTZP dose arm had elevated discontinuation rates due to adverse events. Phase III trials will use a slower dose escalation schedule to improve tolerability, an important design choice for preserving the efficacy-tolerability balance.

Strategic Implications

The incretin market is expanding faster than most analysts modeled at the start of 2026. U.S. obesity incretin prescriptions grew 82% year-over-year, and total U.S. incretin prescriptions grew 32%. The Medicare Bridge Program is a structural demand catalyst, adding roughly 20 million seniors to the addressable obesity market.

Lilly's international share reached approximately 58%, up nearly four percentage points from Q2 2026. This share gain matters because international markets are earlier in their obesity treatment adoption curve, meaning Lilly is establishing brand preference before competitors scale distribution.

The Foundayo oral launch is gaining traction, with four in ten patients starting an oral obesity medicine choosing it. New Foundayo patients doubled from Q2 to Q3, and a U.S. type 2 diabetes approval could arrive in Q4, broadening the label beyond obesity.

Outside cardiometabolic health, the diversified portfolio is gaining scale. Kisunla revenue grew 175% year-over-year in neuroscience, Ebglyss grew 59% in immunology, and Jaypirca grew 59% in oncology. While these are smaller in absolute dollars, they reduce concentration risk and validate Lilly's R&D engine across therapeutic areas.

The two manufacturing facility groundbreakings, $6.5B in Houston and $5B in Richmond, signal that Lilly is investing ahead of demand. Supply has been the binding constraint for incretins industry-wide, and these facilities should support volume growth into the late 2020s.

The AtaiBeckley and Merida acquisitions add neuroplastogen and precision immunology assets, respectively. Neither is near-term revenue, but both fit Lilly's pattern of acquiring differentiated early-stage programs rather than late-stage commercial assets.

Leadership transition is underway, with Patrik Jonsson retiring at year-end and Ilya Yuffa expanding to President of Lilly Global Markets. This consolidates U.S. and international commercial leadership under one executive, which should improve global launch coordination.

What to Watch Next

I would watch four things over the next two quarters:

  • 2027 guidance — Management will provide initial 2027 outlook on the Q4 call in January. The $2B in one-time 2026 items will not recur, so the baseline revenue growth rate will look lower than reported 2026 figures.
  • EloraTZP phase III initiation — The phase II weight loss data of 23.3% is compelling, but tolerability at the highest dose is a risk. The dose escalation design in phase III will determine whether the efficacy profile holds in a broader population.
  • Medicare Bridge Program persistence — Early prescription fills are strong, but refill rates and persistence over six months will determine whether the program converts to durable revenue or produces high discontinuation.
  • Foundayo type 2 diabetes approval — A Q4 FDA action would expand Foundayo beyond obesity and position it as a foundational oral therapy, competing directly with orforglipron's eventual launch.

Related coverage

Source:

Fortune

Get biotech signals in your CRM

FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.

Book a 15 min call
Dominykas Rukas - Revenanas

More from this industry

    We can send changes like these to your own CRM, matched to the accounts your team sells to.

    Book a free audit

    Built in your tools.
    Run by your team.

    Tell us the commercial goal and where it gets stuck. We find the bottleneck with you and plan the first two week sprint from it.

    Dominykas Rukas, RevenanasDominykas RukasCo-founderBook a free audit
    • HubSpot partner badgeHubSpot partner
    • Enterprise Clay partner